We are live on
!
Find out more
State Street SPDR S&P Biotech ETF
292 hedge funds and large institutions have $3.09B invested in State Street SPDR S&P Biotech ETF in 2017 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 100 increasing their positions, 78 reducing their positions, and 48 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more funds holding in top 10
Funds holding in top 10: 6 → 12 (+6)
43% more capital invested
Capital invested by funds: $2.17B → $3.09B (+$922M)
40% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 48
28% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 78
9.07% more ownership
Funds ownership: 88.91% → 97.98% (+9.1%)
7% more funds holding
Funds holding: 274 → 292 (+18)
45% less call options, than puts
Call options by funds: $656M | Put options by funds: $1.19B
Holders
292
Holders Change
+18
Holders Change %
+6.57%
% of All Funds
7.27%
Holding in Top 10
12
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+100%
% of All Funds
0.3%
New
67
Increased
100
Reduced
78
Closed
48
Calls
$656M
Puts
$1.19B
Net Calls
-$530M
Net Calls Change
-$222M
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$150M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$112M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$108M |
| 4 |
AssetMark Inc
Concord,
California
|
+$92.4M |
| 5 |
Citigroup
New York
|
+$68.2M |
